Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Ischemic Stroke Market Research Report Information By Diagnosis (CT, MRI, Carotid Ultrasound, and Cerebral Angiography), By Drug Class (Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032


ID: MRFR/MED/3980-HCR | 120 Pages | Author: Kinjoll Dey| April 2024


Ischemic Stroke Market Segmentation


Global Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




  • CT




  • MRI




  • Carotid Ultrasounds




  • Cerebral Angiography




Global Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




  • Tissue Plasminogen Activator




  • Anticoagulant




  • Antiplatelet




  • Antihypertensive




Global Ischemic Stroke Regional Outlook (USD Billion, 2019-2030)




  • North America Outlook (USD Billion, 2019-2030)




  • North America Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




    • CT




    • MRI




    • Carotid Ultrasounds




    • Cerebral Angiography






  • North America Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




    • Tissue Plasminogen Activator




    • Anticoagulant




    • Antiplatelet




    • Antihypertensive




    • US Outlook (USD Billion, 2019-2030)




    • US Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • US Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive






    • Canada Outlook (USD Billion, 2019-2030)




    • Canada Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • Canada Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive








  • Europe Outlook (USD Billion, 2019-2030)




  • Europe Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




    • CT




    • MRI




    • Carotid Ultrasounds




    • Cerebral Angiography






  • Europe Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




    • Tissue Plasminogen Activator




    • Anticoagulant




    • Antiplatelet




    • Antihypertensive




    • Germany Outlook (USD Billion, 2019-2030)




    • Germany Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • Germany Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive






    • France Outlook (USD Billion, 2019-2030)




    • France Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • France Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive






    • UK Outlook (USD Billion, 2019-2030)




    • UK Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • UK Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive






    • Italy Outlook (USD Billion, 2019-2030)




    • Italy Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • Ct




      • Mri




      • Carotid ultrasounds




      • Cerebral angiography






    • Italy Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive






    • Rest of Europe Outlook (USD Billion, 2019-2030)




    • Rest of Europe Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • Rest of Europe Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive








  • Asia-Pacific Outlook (USD Billion, 2019-2030)




  • Asia-Pacific Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




    • CT




    • MRI




    • Carotid Ultrasounds




    • Cerebral Angiography






  • Asia-Pacific Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




    • Tissue Plasminogen Activator




    • Anticoagulant




    • Antiplatelet




    • Antihypertensive




    • China Outlook (USD Billion, 2019-2030)




    • China Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • China Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive






    • India Outlook (USD Billion, 2019-2030)




    • India Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • India Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive






    • Japan Outlook (USD Billion, 2019-2030)




    • Japan Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • Japan Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive






    • South Korea Outlook (USD Billion, 2019-2030)




    • South Korea Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • South Korea Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive






    • Australia Outlook (USD Billion, 2019-2030)




    • Australia Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • Australia Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive






    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Rest of Asia-Pacific Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • Rest of Asia-Pacific Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive








  • Rest of the World Outlook (USD Billion, 2019-2030)




  • Rest of the World Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




    • CT




    • MRI




    • Carotid Ultrasounds




    • Cerebral Angiography






  • Rest of the World Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




    • Tissue Plasminogen Activator




    • Anticoagulant




    • Antiplatelet




    • Antihypertensive




    • Middle East & Africa Outlook (USD Billion, 2019-2030)




    • Middle East & Africa Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • Middle East & Africa Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive






    • Latin America Outlook (USD Billion, 2019-2030)




    • Latin America Ischemic Stroke, By Diagnosis Outlook (USD Billion, 2019-2030)




      • CT




      • MRI




      • Carotid Ultrasounds




      • Cerebral Angiography






    • Latin America Ischemic Stroke, By Drug Class (USD Billion, 2019-2030)




      • Tissue Plasminogen Activator




      • Anticoagulant




      • Antiplatelet




      • Antihypertensive







Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Surgery Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 7. Global Ischemic Stroke Market, By Diagnosis

7.1 Introduction

7.2 Computed Tomography (CT)

7.3.1 Market Estimates & Forecast, 2023 - 2030

7.3 Magnetic Resonance Imaging (MRI)

7.3.1 Market Estimates & Forecast, 2023 - 2030

7.4 Carotid Ultrasound

7.4.1 Market Estimates & Forecast, 2023 - 2030

7.5 Cerebral Angiography

7.5.1 Market Estimates & Forecast, 2023 - 2030

7.6 Electrocardiography

7.7.1 Market Estimates & Forecast, 2023 - 2030

7.8 Echocardiography

7.8.1 Market Estimates & Forecast, 2023 - 2030

7.4 Others

Chapter 8. Global Ischemic Stroke Market, By Drug Class

8.1 Introduction

8.2 Tissue Plasminogen Activator

8.2.1 Market Estimates & Forecast, 2023 - 2030

8.3 Anticoagulant

8.3.1 Market Estimates & Forecast, 2023 - 2030

8.4 Antiplatelet

8.4.1 Market Estimates & Forecast, 2023 - 2030

8.5 Antihypertensive

8.5.1 Market Estimates & Forecast, 2023 - 2030

8.6 Others

Chapter 9. Global Ischemic Stroke Market, By Surgery

9.1 Introduction

9.2 Carotid Endarterectomy

9.2.1 Market Estimates & Forecast, 2023 - 2030

9.3 Angioplasty

9.3.1 Market Estimates & Forecast, 2023 - 2030

9.4 Endovascular Mechanical Thrombectomy

9.4.1 Market Estimates & Forecast, 2023 - 2030

Chapter 10. Global Ischemic Stroke Market, By End User

10.1 Introduction

10.2 Hospitals & Clinics

10.2.1 Market Estimates & Forecast, 2023 - 2030

10.3 Medical Institutes

10.3.1 Market Estimates & Forecast, 2023 - 2030

10.4 Research Organization

10.4.1 Market Estimates & Forecast, 2023 - 2030

10.5 Others

10.5.1 Market Estimates & Forecast, 2023 - 2030

Chapter. 11 Global Ischemic Stroke Market, By Region

11.1 Introduction

11.2 Americas

11.2.1 North America

11.2.1.1 U.S.

11.2.1.2 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 U.K

11.3.1.6 Rest Of Western Europe

11.3.2 Eastern Europe

11.4 Asia Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic Of Korea

11.4.6 Rest Of Asia Pacific

11.5 The Middle East & Africa

11.5.1 United Arab Emirates

11.5.2 Saudi Arabia

11.5.3 Rest Of The Middle East & Africa

Chapter 12 Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

12.3.1 Key Developments

Chapter 13 Company Profiles

13.1 Abbott Laboratories

13.1.1 Company Overview

13.1.2 Drug Class Overview

13.1.3 Financials

13.1.4 SWOT Analysis

13.2 Medtronic Plc

13.2.1 Company Overview

13.2.2 Drug Class Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Boston Scientific Corporation

13.3.1 Company Overview

13.3.2 Drug Class Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 Cordis Corporation

13.4.1 Company Overview

13.4.2 Drug Class/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 Merck & Co., Inc.

13.5.1 Company Overview

13.5.2 Drug Class Overview

13.5.3 Financial Overview

13.5.4 Key Developments

13.6 Koninklijke Philips N.V.

13.6.1 Company Overview

13.6.2 Drug Class Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.7 GE Healthcare

13.7.1 Overview

13.7.2 Drug Class Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 Stryker Corporation

13.8.1 Company Overview

13.8.2 Drug Class/Business Segment Overview

13.8.3 Financial Overview

13.8.4 Key Development

13.8.5 SWOT Analysis

13.9 Pfizer Inc.

13.9.1 Company Overview

13.9.2 Drug Class Overview

13.9.3 Financial Overview

13.9.4 Key Developments

13.10 Others

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs Of The Market

14.2 Key Companies To Watch

14.3 Prediction Of Pharmaceutical Industry

Chapter 15 Appendix

LIST OF TABLES

Table 1 Ischemic Stroke Industry Synopsis, 2023 - 2030

Table 2 Ischemic Stroke Market Estimates And Forecast, 2023 - 2030, (USD Million)

Table 3 Ischemic Stroke Market By Region, 2023 - 2030, (USD Million)

Table 4 Ischemic Stroke Market By Diagnosis, 2023 - 2030, (USD Million)

Table 5 Ischemic Stroke Market By Drug Class, 2023 - 2030, (USD Million)

Table 6 Ischemic Stroke Market By Surgery, 2023 - 2030, (USD Million)

Table 7 Ischemic Stroke Market By End Users, 2023 - 2030, (USD Million)

Table 8 North America Ischemic Stroke Market By Diagnosis, 2023 - 2030, (USD Million)

Table 9 North America Ischemic Stroke Market By Drug Class, 2023 - 2030, (USD Million)

Table 10 North America Ischemic Stroke Market By Surgery, 2023 - 2030, (USD Million)

Table 11 North America Ischemic Stroke Market By End User, 2023 - 2030, (USD Million)

Table 12 US Ischemic Stroke Market By Diagnosis, 2023 - 2030, (USD Million)

Table 13 US Ischemic Stroke Market By Drug Class, 2023 - 2030, (USD Million)

Table 14 US Ischemic Stroke Market By Surgery, 2023 - 2030, (USD Million)

Table 15 US Ischemic Stroke Market By End User, 2023 - 2030, (USD Million)

Table 16 Canada Ischemic Stroke Market By Diagnosis, 2023 - 2030, (USD Million)

Table 17 Canada Ischemic Stroke Market By Drug Class, 2023 - 2030, (USD Million)

Table 18 Canada Ischemic Stroke Market By Surgery, 2023 - 2030, (USD Million)

Table 19 Canada Ischemic Stroke Market By End User, 2023 - 2030, (USD Million)

Table 20 South America Ischemic Stroke Market By Diagnosis, 2023 - 2030, (USD Million)

Table 21 South America Ischemic Stroke Market By Drug Class, 2023 - 2030, (USD Million)

Table 22 South America Ischemic Stroke Market By Surgery, 2023 - 2030, (USD Million)

Table 23 South America Ischemic Stroke Market By End User, 2023 - 2030, (USD Million)

Table 24 Europe Ischemic Stroke Market By Diagnosis, 2023 - 2030, (USD Million)

Table 25 Europe Ischemic Stroke Market By Drug Class, 2023 - 2030, (USD Million)

Table 26 Europe Ischemic Stroke Market By Surgery, 2023 - 2030, (USD Million)

Table 27 Europe Ischemic Stroke Market By End User, 2023 - 2030, (USD Million)

Table 28 Western Europe Ischemic Stroke Market By Diagnosis, 2023 - 2030, (USD Million)

Table 29 Western Europe Ischemic Stroke Market By Drug Class, 2023 - 2030, (USD Million)

Table 30 Western Europe Ischemic Stroke Market By Surgery, 2023 - 2030, (USD Million)

Table 31 Western Europe Ischemic Stroke Market By End User, 2023 - 2030, (USD Million)

Table 32 Eastern Europe Ischemic Stroke Market By Diagnosis, 2023 - 2030, (USD Million)

Table 33 Eastern Europe Ischemic Stroke Market By Drug Class, 2023 - 2030, (USD Million)

Table 34 Eastern Europe Ischemic Stroke Market By Surgery, 2023 - 2030, (USD Million)

Table 35 Eastern Europe Ischemic Stroke Market By End User, 2023 - 2030, (USD Million)

Table 36 Asia Pacific Ischemic Stroke Market By Diagnosis, 2023 - 2030, (USD Million)

Table 37 Asia Pacific Ischemic Stroke Market By Drug Class, 2023 - 2030, (USD Million)

Table 38 Asia Pacific Ischemic Stroke Market By Surgery, 2023 - 2030, (USD Million)

Table 39 Asia Pacific Ischemic Stroke Market By End User, 2023 - 2030, (USD Million)

Table 40 The Middle East & Africa Ischemic Stroke Market By Diagnosis, 2023 - 2030, (USD Million)

Table 41 The Middle East & Africa Ischemic Stroke Market By Drug Class, 2023 - 2030, (USD Million)

Table 42 The Middle East & Africa Ischemic Stroke Market By Surgery, 2023 - 2030, (USD Million)

Table 43 The Middle East & Africa Ischemic Stroke Market By End User, 2023 - 2030, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation For Ischemic Stroke Market

Figure 3 Segmentation Market Dynamics For Ischemic Stroke Market

Figure 4 Global Ischemic Stroke Market Share, By Diagnosis 2023

Figure 6 Global Ischemic Stroke Market Share, By Drug Class 2023

Figure 7 Global Ischemic Stroke Market Share, By Surgery, 2023

Figure 8 Global Ischemic Stroke Market Share, By End Users, 2023

Figure 9 Global Ischemic Stroke Market Share, By Region, 2023

Figure 10 North America Ischemic Stroke Market Share, By Country, 2023

Figure 11 Europe Ischemic Stroke Market Share, By Country, 2023

Figure 12 Asia Pacific Ischemic Stroke Market Share, By Country, 2023

Figure 13 The Middle East & Africa Ischemic Stroke Market Share, By Country, 2023

Figure 14 Global Ischemic Stroke Market: Company Share Analysis, 2023 (%)

Figure 15 Abbott Laboratories: Key Financials

Figure 16 Abbott Laboratories: Segmental Revenue

Figure 17 Abbott Laboratories: Geographical Revenue

Figure 18 Medtronic Plc: Key Financials

Figure 19 Medtronic Plc: Segmental Revenue

Figure 20 Medtronic Plc: Geographical Revenue

Figure 21 Boston Scientific Corporation: Key Financials

Figure 22 Boston Scientific Corporation: Segmental Revenue

Figure 23 Boston Scientific Corporation: Geographical Revenue

Figure 24 Cordis Corporation: Key Financials

Figure 25 Cordis Corporation: Segmental Revenue

Figure 26 Cordis Corporation: Geographical Revenue

Figure 27 Merck & Co., Inc.: Key Financials

Figure 28 Merck & Co., Inc.: Segmental Revenue

Figure 29 Merck & Co., Inc.: Geographical Revenue

Figure 30 Koninklijke Philips N.V.: Key Financials

Figure 31 Koninklijke Philips N.V.: Segmental Revenue

Figure 32 Koninklijke Philips N.V.: Geographical Revenue

Figure 33 GE Healthcare: Key Financials

Figure 34 GE Healthcare: Segmental Revenue

Figure 35 GE Healthcare: Geographical Revenue

Figure 36 Stryker Corporation: Key Financials

Figure 37 Stryker Corporation: Segmental Revenue

Figure 38 Stryker Corporation: Geographical Revenue

Figure 39 Pfizer Inc.: Key Financials

Figure 40 Pfizer Inc.: Segmental Revenue

Figure 41 Pfizer Inc.: Geographical Revenue

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.